No abstract

A mixed valence tetranuclear iron complex [(Hpmide)FeII(NCSe)2FeIII(pmide)]2•5CH3OH (1) that undergoes oxidation and ligand exchange in the solid state (H2pmide = N-(2-pyridylmethyl)iminodiethanol). Upon air oxidation, 1 was converted into [(pmide)FeIII(NCSe)FeIII(pmide)]2(NCSe)2•2H2O (2),...

A one-dimensional (1D) coordination polymer [Cu2(bpba)(CH3COO)4] (1) and a two-dimensional (2D) coordination polymer [Cu(bpba)2(H2O)(NO3)](NO3)∙2H2O∙MeOH (2) were synthesized by the reaction between Cu(CH3COO)2∙H2O/Cu(NO3)2∙3H2O and bis(4-pyridyl)benzylamine (bpba). The Cu(II) ions of 1 and 2 have distorted-square pyramidal coordination with a paddle-wheel structure and an octahedral geometry, respectively. By coordinating the Cu(II) ions and bpba ligands, 1 and 2 formed zigzag 1D and puckered 2D coordination polymers, respectively. Polymer 1 exhibits strong emissions at 355 and 466 nm, whereas polymer 2 exhibits strong emissions only at 464 nm. The emissions are strongly dependent on the geometry of the Cu(II) ions linked by the bpba and anionic ligands. Polymer 1 exhibits a very strong antiferromagnetic interaction within the paddle-wheel dimer, whereas polymer 2 exhibits a very weak antiferromagnetic interaction through the bpba linkers and/or space.

High morbidity rates are associated with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. New studies have suggested that dysbiosis may play a role in the etiology of inflammatory bowel disease, although the cause of IBD remains unknown. Several disease pathologies, such as inflammatory bowel disease, have been associated with the intestinal microbiota, a metabolic organ with multiple physiological functions. This review summarizes the present level of knowledge regarding the impact of altered gut microbiota in inflammatory bowel disease, the mechanisms by which this occurs, and the potential significance of therapeutic methods based on gut microbiota in the prevention and treatment of IBD. It has been demonstrated that directly targeting the intestinal microbiota can treat both inflammatory bowel disease and colitis in humans and animals. To characterize the core microbiome associated with IBD and the underlying pathophysiology, however, additional research employing well-designed randomized control trials and animal models is required, as there are currently insufficient data and contradictory results from previous studies. The environment will influence the probiotic and prebiotic treatment for IBD.